Antimicrob Agents Chemother. 2015 Jan 20. pii: AAC.04568-14. [Epub ahead of print]
Antimicrobial activity of solithromycin tested against serotyped macrolide-resistant Streptococcus pneumoniae collected from medical centers across the USA (2012).
Farrell DJ1, Mendes RE2, Jones RN2.
Author information
Abstract
Solithromycin, a fourth-generation macrolide and novel fluoroketolide, was tested against a 2012 collection of serotyped United States macrolide-resistant S. pneumoniae isolates associated with community-acquired bacterial pneumonia (CABP). Against all 272 isolates, solithromycin demonstrated high potency (MIC50/90, 0.06/0.25 μg/mL) and inhibited all strains at MIC values ≤0.5 μg/mL, including against the two most prevalent macrolide-resistant serotypes (19A and 35B). This data supports continued clinical development of solithromycin for the treatment of multidrug resistant CABP.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
PMID: 25605359 [PubMed - as supplied by publisher]
No comments:
Post a Comment